非小细胞肺癌中Reprimo以及14-3-3 Σ基因启动子异常甲基化检测

Detection of Aberrant Methylation of Reprimo and 14-3-3 Σ Genes in Non-small Cell Lung Cancer

目的探讨Reprimo以及14-3-3 Σ基因启动子在非小细胞肺癌(NSCLC)中的异常甲基化状态及其与临床病理资料的联系。方法采用甲基化特异性聚合酶链反应(Methylation Specific-PCR,MSP)技术检测60例NSCLC以及癌旁正常组织中Reprimo以及14-3-3 Σ基因启动子异常甲基化状态。结果Reprimo以及14-3-3 Σ基因启动子异常甲基化在NSCLC组织中发生频率分别为36.67%(22/60)和28.33%(17/60),与癌旁正常组织具有显著性差异(P值分别为0.000和0.002)。Reprimo基因启动子异常甲基化频率与吸烟习惯以及年龄相关;14-3-3 Σ启动子异常甲基化与年龄、吸烟习惯、性别、病理类型和临床分期以及淋巴结转移等无相关。结论NSCLC中存在Reprimo和14-3-3 Σ等基因启动子较高频率的异常甲基化。

Objective To investigate the frequency of aberrant methylation of Reprimo and 14 3-3 ∑ in non-small cell lung cancer （NSCLC）. Methods Aberrant methylation of Reprimo and 14-3-3 ∑ were examined by methylation specific-PCR （MSP） in primary NSCLC and normal lung tissues （n = 60）. Results Aberrant methylation of Reprimo and 14-3 3 ∑were found to he present in 36. 67% and 28. 33% of all NSCLC patients respectively. Three cases of Aberrant methylation of Reprimo（5 %） and 4 cases of 14-3- 3 ∑（6. 67%） were detected in normal lung tissues. The frequencies of aberrant methylation of Reprimo and 14-3-3 ∑between primary NSCLC and normal lung tissue group were significantly different. Aberrant methylation of Re＇primo was more frequently observed in older patients group （P = 0. 047） and smok ing group （P = 0. 038）. There was no significant correlation between Reprimo methylation frequencies and sex, pathology type, clinical staging and lymphatic metastasis. Similarly no significant association was found between 14-3 3 ∑ methylation frequencies and sex, age, pathology type, clinical staging, smoking habit and lymphatic metastasis. Conclusion Methylation of Reprimo and 14-3-3 ∑ may play an important role in the pathogenesis of NSCLC.